Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Sirolimus

abstract

  • These results established the efficacy and safety of everolimus in patients with mRCC after progression on sunitinib and/or sorafenib.

publication date

  • September 15, 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.25219

PubMed ID

  • 20549832

Additional Document Info

start page

  • 4256

end page

  • 65

volume

  • 116

number

  • 18